Novabay Pharma Financials
This page shows Novabay Pharma (NBY) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Gross profit is positive, but operating costs and financing—not sales—determine the business’s cash position.
In FY2024, operating cash flow was-$7.5M against a net loss of-$7.2M , so reported losses closely matched cash leaving the business. Because this occurred despite a66.3% gross margin, the central pressure sits below gross profit rather than in direct production costs.
Gross margin rose from
Negative operating cash flow persisted from FY2021 through FY2025 while financing inflows appeared in every reported year, meaning operations did not self-fund. FY2025 cash was
Financial Health Signals
Novabay Pharma does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The metrics below are current.
Key Financial Metrics
Earnings & Revenue
None of these metrics is reported for fiscal year 2025.
Cash & Balance Sheet
Novabay Pharma held $8.0M in cash as of fiscal year 2025; long-term debt is not reported for that period.
Novabay Pharma paid $4.00 per share in dividends in fiscal year 2025.
Not reported for fiscal year 2025.
Margins & Returns
None of these metrics is reported for fiscal year 2025.
Capital Allocation
None of these metrics is reported for fiscal year 2025.
NBY Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | N/A | N/A | $9.8M-6.4% | $10.5M-27.4% | $14.4M+41.2% | $10.2M+2.7% | $9.9M+50.5% | $6.6M-47.2% | $12.5M-31.4% | $18.2M+53.2% | $11.9M+171.6% | $4.4M+315.7% | $1.1M-69.7% | $3.5M-49.8% | $6.9M-37.1% | $11.0M |
| Cost of Revenue | N/A | N/A | $3.3M-24.5% | $4.4M-34.0% | $6.6M+79.5% | $3.7M-7.1% | $4.0M+128.4% | $1.7M+15.6% | $1.5M-46.0% | $2.8M+13.0% | $2.5M+95.4% | $1.3M+159.5% | $486K+200.0% | $162K+1925.0% | $8K | N/A |
| Gross Profit | N/A | N/A | $6.5M+6.5% | $6.1M-21.8% | $7.8M+19.4% | $6.5M+9.2% | $6.0M+22.7% | $4.9M-55.8% | $11.0M-28.8% | $15.4M+63.7% | $9.4M+202.3% | $3.1M+449.3% | $568K-82.9% | $3.3M+55150.0% | $6K | N/A |
| R&D Expenses | N/A | N/A | $42K+23.5% | $34K-80.5% | $174K+295.5% | $44K-84.6% | $285K+54.9% | $184K-29.0% | $259K-36.8% | $410K-70.1% | $1.4M-76.1% | $5.7M-39.6% | $9.5M-23.9% | $12.5M+34.4% | $9.3M-6.4% | $9.9M |
| SG&A Expenses | N/A | $7.6M+2.8% | $7.4M+35.5% | $5.4M-27.3% | $7.5M+3.4% | $7.2M+22.0% | $5.9M+11.7% | $5.3M-8.9% | $5.8M-32.5% | $8.6M+19.4% | $7.2M-60.0% | $18.1M+128.0% | $7.9M+25.2% | $6.3M+6.1% | $6.0M+10.0% | $5.4M |
| Operating Income | N/A | -$8.4M-14.4% | -$7.4M-79.9% | -$4.1M+71.5% | -$14.4M-62.7% | -$8.9M-37.9% | -$6.4M+31.6% | -$9.4M-19.4% | -$7.9M-7.7% | -$7.3M+33.4% | -$11.0M+48.0% | -$21.1M-25.0% | -$16.9M-9.2% | -$15.5M-86.4% | -$8.3M-92.3% | -$4.3M |
| Income Tax | N/A | $0 | $0 | $0 | $0 | $0-100.0% | $5K-16.7% | $6K+50.0% | $4K+33.3% | $3K+50.0% | $2K0.0% | $2K0.0% | $2K+25.0% | $2K-20.0% | $2K0.0% | $2K |
| Net Income | N/A | N/A | -$7.2M+25.1% | -$9.6M+9.1% | -$10.6M-82.1% | -$5.8M+47.2% | -$11.0M-14.3% | -$9.7M-47.6% | -$6.5M+11.6% | -$7.4M+43.7% | -$13.2M+30.7% | -$19.0M-24.9% | -$15.2M+5.3% | -$16.0M-128.3% | -$7.0M-38.2% | -$5.1M |
| EPS (Diluted) | — | N/A | N/A | N/A | N/A | N/A | -$0.31 | -$0.48-4.3% | -$0.46+4.2% | -$0.48 | -$1.40 | -$6.82+10.8% | -$7.65+27.2% | -$10.51 | -$0.24-20.0% | -$0.20 |
Not reported in any period shown, so not listed: Interest Expense.
TTM is the trailing twelve months, Q2 FY2025 through Q1 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
NBY Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | $9.0M+163.9% | $3.4M-62.1% | $9.0M-44.9% | $16.4M-31.6% | $24.0M+57.4% | $15.2M+35.8% | $11.2M+19.9% | $9.4M-7.1% | $10.1M-34.5% | $15.4M+203.0% | $5.1M-32.6% | $7.5M-51.8% | $15.7M-18.6% | $19.2M+20.5% | $16.0M |
| Current Assets | $8.7M+348.3% | $1.9M-73.0% | $7.2M-36.9% | $11.3M-14.0% | $13.2M-7.5% | $14.2M+51.8% | $9.4M+9.0% | $8.6M-4.3% | $9.0M-37.8% | $14.5M+219.7% | $4.5M-34.9% | $7.0M-53.0% | $14.8M-19.1% | $18.3M+25.6% | $14.6M |
| Cash & Equivalents | $8.0M+1750.7% | $430K-85.3% | $2.9M-45.5% | $5.4M-28.5% | $7.5M-37.2% | $12.0M+72.3% | $6.9M+117.9% | $3.2M-0.5% | $3.2M-66.4% | $9.5M+298.8% | $2.4M-56.1% | $5.4M-48.3% | $10.5M-17.6% | $12.7M+51.1% | $8.4M |
| Inventory | N/A | $0-100.0% | $501K-85.4% | $3.4M+6.7% | $3.2M+429.6% | $608K+23.6% | $492K+75.7% | $280K-44.4% | $504K-42.3% | $873K-35.1% | $1.3M+158.2% | $521K+125.5% | $231K+904.3% | $23K | N/A |
| Accounts Receivable | N/A | N/A | $680K-65.5% | $2.0M | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Goodwill | N/A | N/A | $0-100.0% | $348K-92.3% | $4.5M | $0 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $640.5M+17932.1% | $3.6M-37.9% | $5.7M-2.1% | $5.8M-57.7% | $13.8M+372.8% | $2.9M-71.5% | $10.2M+132.5% | $4.4M-41.1% | $7.5M-9.6% | $8.3M-18.6% | $10.2M+78.9% | $5.7M-20.3% | $7.1M+37.6% | $5.2M-21.6% | $6.6M |
| Current Liabilities | $1.1M-59.8% | $2.8M-33.5% | $4.3M+0.5% | $4.3M+23.7% | $3.4M+21.5% | $2.8M-50.2% | $5.7M+47.8% | $3.8M-22.7% | $5.0M+15.2% | $4.3M-6.7% | $4.6M+38.5% | $3.3M-7.8% | $3.6M+14.3% | $3.2M+11.8% | $2.8M |
| Total Equity | -$631.8M-489679.1% | -$129K-103.9% | $3.3M-68.6% | $10.6M+3.8% | $10.2M-17.4% | $12.3M+1166.0% | $973K-80.4% | $5.0M+91.0% | $2.6M-63.5% | $7.1M+239.3% | -$5.1M-375.9% | $1.8M-78.3% | $8.5M-39.4% | $14.0M+50.4% | $9.3M |
| Retained Earnings | -$819.1M-346.5% | -$183.5M-4.9% | -$174.8M-10.6% | -$158.2M-11.5% | -$141.9M-4.3% | -$136.1M-8.8% | -$125.0M-8.7% | -$115.0M-3.5% | -$111.1M-7.1% | -$103.7M-14.5% | -$90.5M-26.5% | -$71.5M | N/A | N/A | N/A |
Not reported in any period shown, so not listed: Long-Term Debt.
NBY Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$8.9M | -$8.4M-12.4% | -$7.5M-81.5% | -$4.1M+37.9% | -$6.7M+27.6% | -$9.2M-94.7% | -$4.7M+40.5% | -$7.9M-42.4% | -$5.6M+11.2% | -$6.3M+46.2% | -$11.7M+37.2% | -$18.6M-23.3% | -$15.1M-16.1% | -$13.0M-98.7% | -$6.5M-107.8% | -$3.1M |
| Capital Expenditures | N/A | N/A | $6K-68.4% | $19K-83.0% | $112K+115.4% | $52K+100.0% | $26K+36.8% | $19K-56.8% | $44K-82.0% | $244K+52.5% | $160K+30.1% | $123K+80.9% | $68K-51.8% | $141K-4.7% | $148K+24.4% | $119K |
| Free Cash Flow | N/A | N/A | -$7.5M-80.8% | -$4.2M+38.7% | -$6.8M+26.8% | -$9.2M-94.7% | -$4.7M+40.3% | -$7.9M-41.6% | -$5.6M+13.8% | -$6.5M+44.9% | -$11.8M+36.7% | -$18.7M-23.5% | -$15.1M-15.4% | -$13.1M-96.4% | -$6.7M-104.7% | -$3.3M |
| Investing Cash Flow | N/A | N/A | $1.1M+5700.0% | -$19K+83.0% | -$112K+99.1% | -$12.0M-46226.9% | -$26K-36.8% | -$19K+56.8% | -$44K+82.0% | -$244K-52.5% | -$160K-86.0% | -$86K-103.3% | $2.6M+84.6% | $1.4M+3.2% | $1.4M+129.2% | -$4.7M |
| Financing Cash Flow | $44.7M | $4.6M+207.9% | $1.5M-21.5% | $1.9M-58.8% | $4.6M-72.4% | $16.8M+72.0% | $9.8M-16.6% | $11.7M+109.1% | $5.6M+2684.6% | $201K-99.0% | $19.4M+24.5% | $15.6M+111.2% | $7.4M-20.8% | $9.3M-1.5% | $9.5M+101.5% | $4.7M |
| Dividends Paid | N/A | $4.8M | $0 | N/A | N/A | N/A | N/A | $0 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Not reported in any period shown, so not listed: Share Buybacks.
TTM is the trailing twelve months, Q2 FY2025 through Q1 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
NBY Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | 66.3%+8.1pp | 58.2%+4.2pp | 54.0%-9.8pp | 63.8%+3.8pp | 60.0%-13.6pp | 73.7%-14.3pp | 88.0%+3.2pp | 84.7%+5.4pp | 79.3%+8.1pp | 71.2%+17.3pp | 53.9%-41.4pp | 95.3%+95.3pp | 0.1% | N/A |
| Operating Margin | N/A | -75.4%-36.2pp | -39.2% | -100.1% | -86.9%-22.2pp | -64.7% | -142.5% | -62.9%-22.8pp | -40.1%+52.2pp | -92.3% | -482.5% | -1603.8% | -445.4% | -119.8% | -39.2% |
| Net Margin | N/A | -73.9%+18.4pp | -92.2%-18.6pp | -73.7%-16.6pp | -57.1% | -111.1% | -146.4% | -52.3%-11.7pp | -40.6% | -110.5% | -433.1% | -1441.6% | -461.4% | -101.4% | -46.2% |
| Return on Equity | N/A | N/A | -290.9%-190.4pp | -100.5%-43.3pp | -57.3%+32.4pp | -89.6%+903.0pp | -992.6%-860.5pp | -132.1%+153.3pp | -285.4%-100.2pp | -185.2% | N/A | -822.2%-633.8pp | -188.4%-138.3pp | -50.0%+4.4pp | -54.4% |
| Return on Assets | N/A | -211.0%-104.3pp | -106.7%-42.0pp | -64.7%-40.4pp | -24.3%+48.2pp | -72.4%+13.6pp | -86.1%-16.2pp | -69.9%+3.5pp | -73.5%+12.0pp | -85.5%+288.2pp | -373.7%-172.1pp | -201.6%-99.1pp | -102.5%-66.0pp | -36.5%-4.7pp | -31.9% |
| Current Ratio | 7.60+6.9x | 0.68-1.0x | 1.67-1.0x | 2.66-1.2x | 3.83-1.2x | 5.03+3.4x | 1.65-0.6x | 2.24+0.4x | 1.81-1.5x | 3.35+2.4x | 0.98-1.1x | 2.08-2.0x | 4.08-1.7x | 5.76+0.6x | 5.13 |
| Debt-to-Equity | N/A | N/A | 1.73+1.2x | 0.55-0.8x | 1.36+1.1x | 0.24-10.3x | 10.53+9.6x | 0.89-2.0x | 2.89+1.7x | 1.17 | N/A | 3.08+2.2x | 0.84+0.5x | 0.37-0.3x | 0.71 |
| FCF Margin | N/A | -76.7%-37.0pp | -39.7%+7.3pp | -47.0%+43.6pp | -90.6%-42.8pp | -47.8% | -120.4% | -44.9%-9.1pp | -35.7%+63.6pp | -99.4% | -426.4% | -1434.8% | -377.1% | -96.3%-66.7pp | -29.6% |
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.
Note: Shareholder equity is negative (-$631.8M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Similar Companies
Where Novabay Pharma Ranks
Frequently Asked Questions
Does Novabay Pharma pay dividends?
Yes, Novabay Pharma (NBY) paid $4.00 per share in dividends during fiscal year 2025.
What is Novabay Pharma's operating cash flow?
Novabay Pharma (NBY) recorded an outflow of $8.4M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Novabay Pharma's total assets?
Novabay Pharma (NBY) had $9.0M in total assets as of fiscal year 2025, including both current and long-term assets.
What is Novabay Pharma's current ratio?
Novabay Pharma (NBY) had a current ratio of 7.60 as of fiscal year 2025, which is generally considered healthy.
What is Novabay Pharma's cash runway?
Based on fiscal year 2025 data, Novabay Pharma (NBY) had $8.0M in cash against an annual operating cash burn of $8.4M. This gives an estimated cash runway of approximately 11 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
Why is Novabay Pharma's debt-to-equity ratio negative or not reported?
Novabay Pharma (NBY) has negative shareholder equity of -$631.8M as of fiscal year 2025, so no debt-to-equity ratio is reported: dividing debt by equity that is not positive produces a number that cannot be read as leverage. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.